PHIO, a biotechnology company in its sector, demonstrates strong performance in debt and income ratios but fails Shariah compliance due to excessive liquidity holdings exceeding all major thresholds. Business activities in R&D appear permissible with no non-compliant revenue identified. Index research confirms exclusion from all major Shariah indices, leading to a non-compliant overall status. Purification is not required given zero non-permissible income, but investors should monitor liquidity management. The compliance quality rating reflects solid fundamentals offset by financial structure concerns.